A Safety, Tolerability, Pharmacokinetic Study of SHR-6934 Injection in Healthy Subjects

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions

Heart Failure

Interventions

DRUG

SHR-6934 injection

DRUG

SHR-6934 placebo

Trial Locations (1)

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

Beijing Suncadia Pharmaceuticals Co., Ltd

INDUSTRY

NCT06700083 - A Safety, Tolerability, Pharmacokinetic Study of SHR-6934 Injection in Healthy Subjects | Biotech Hunter | Biotech Hunter